Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Nordic Nanovector ASA (OSE: NANOV) today provides an update following its comprehensive review and independent data evaluation of PARADIGME, its...
Nordic Nanovector ASA (OSE: NANOV) announces an update from the LYMRIT 37-05 Phase 1 trial investigating Betalutin® (177Lu lilotomab satetraxetan) in ...
Nordic Nanovector ASA (OSE: NANOV) today provides an update on PARADIGME, its ongoing Phase 2b trial of Betalutin® (177Lu lilotomab satetraxetan) in...
Reference is made to the minutes from Nordic Nanovector ASA's (the "Company") (OSE: NANOV) annual general meeting held on 28 April 2022 in Oslo,...
Nordic Nanovector ASA (OSE: NANOV) announces its results for the first quarter 2022. A presentation by Nordic Nanovector's senior management team...
Nordic Nanovector ASA (OSE: NANOV) announces that it will report its results for the first quarter 2022 on Friday, 13 May 2022. A presentation by...
Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune...
The Annual General Meeting (the "AGM") of Nordic Nanovector ASA (the "Company") (OSE: NANOV) was held today on 28 April 2022 in Oslo, Norway. All...
Notice is given that the Annual General Meeting of Nordic Nanovector ASA will be held on 28 April 2022, at 14:00 hours CEST at Advokatfirmaet Selmer, ...
On 5 April 2022, the Board of Directors of Nordic Nanovector ASA approved the Company's financial statements for 2021. The Company's 2021 Annual...
Nordic Nanovector ASA (OSE: NANOV) announces that its Nomination Committee has nominated Dr Thomas Ramdahl for election as a Non-executive Director...
Reference is made to the stock exchange announcement made by Nordic Nanovector ASA's (OSE: NANOV) (the "Company") on 31 January 2019, regarding...
The Board of Directors of Nordic Nanovector ASA ("Nordic Nanovector" or the "Company") has on 10 March 2022 decided to grant 934,000 Performance...
Nordic Nanovector ASA (OSE: NANOV) announces its results for the fourth quarter and full year 2021. A live webcast presentation by Nordic...
Nordic Nanovector ASA (OSE: NANOV) announces that it will report its results for the fourth quarter and full year 2021 on Tuesday, 1 March 2022. A...
Nordic Nanovector ASA (the "Company") announces that an extraordinary general meeting ("EGM") in the Company was held today at the Company's offices...
Nordic Nanovector ASA (OSE: NANOV) provides an update on the timeline for PARADIGME, its ongoing pivotal Phase 2b trial of Betalutin® (177Lu...
Nordic Nanovector ASA (OSE: NANOV), clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases, ...
Nordic Nanovector ASA (OSE: NANOV), a clinical stage biotechnology company developing targeted radiopharmaceuticals to extend and improve the lives...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.